Exane Derivatives’s IGM Biosciences IGMS Stock Holding History

Exane Derivatives’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$865	Hold	48	–	–	﹤0.01%	521
2022 Q1	$1.28K	Hold	48	–	–	﹤0.01%	784
2021 Q4	$1.41K	Hold	48	–	–	﹤0.01%	684
2021 Q3	$3.16K	Hold	48	–	–	﹤0.01%	767
2021 Q2	$4.01K	Sell	48 -785	-94%	-$58.2K	﹤0.01%	786
2021 Q1	$63.9K	Sell	833 -1,037	-55%	-$94.4K	0.02%	494
2020 Q4	$165K	Hold	1,870	–	–	0.05%	335
2020 Q3	$138K	Sell	1,870 -82	-4%	-$4.85K	0.04%	247
2020 Q2	$142K	Buy	1,952 +322	+20%	+$19.6K	0.04%	241
2020 Q1	$91.5K	Buy	+1,630	New	+$71.4K	0.03%	290

Other funds holding IGMS

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Exane Derivatives's IGMS Position: Q2 2022 in Review

Exane Derivatives held its IGM Biosciences (IGMS) position steady in Q2 2022 at 48 shares worth $865. The position accounts for ﹤0.01% of the portfolio, ranked #521.

Exane Derivatives first reported a position in IGMS in Q1 2020 and has held it in 10 quarters since. The position peaked at $165K in Q4 2020. 89 funds tracked by Wall St. Rank hold IGMS as of Q2 2022.

Exane Derivatives held 48 shares of IGM Biosciences worth $865 as of Q2 2022.
Exane Derivatives left its IGM Biosciences share count unchanged in Q2 2022.
IGM Biosciences made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #521 holding.
Exane Derivatives first reported a position in IGM Biosciences in Q1 2020 and has held it in 10 quarters since.
Exane Derivatives's IGM Biosciences position peaked at $165K in Q4 2020.
89 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.